12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ad-IL-12: Phase I/II data

Ziopharm reported data from 13 patients in the dose-escalation Phase I portion of an open-label, U.S. Phase I/II trial showing that 5 of 7 patients receiving intratumoral injections of Ad-RTS-IL-12 plus the 2 highest doses of an oral activator ligand (INXN-1001) had signs of "clinical activity." No dose-limiting toxicities (DLTs) were reported, but there were 3...

Read the full 259 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >